10-Q: Solana Company pivots to SOL treasury; big Q3 loss

Solana Company transformed into a Solana token treasury vehicle, raised over $500M via PIPE/ATM, amassed $350M of SOL by 9/30, but recorded a $352.8M Q3 net loss driven by derivative warrant liabilities and financing costs.

Summary

• Rebranded from Helius Medical Technologies to Solana Company and launched a digital asset treasury strategy centered on Solana (SOL), while continuing PoNS neurotechnology commercialization.
• Raised gross proceeds of $502.8M on Sep 18, 2025 via PIPE (cash and crypto), including $113.0M in contributed digital assets; net cash proceeds were $374.9M after $14.9M cash offering costs.
• As of Sep 30, 2025: cash and cash equivalents $124.1M; working capital $122.5M; held 1,739,355 SOL (fair value $350.2M), of which 345,551 SOL were restricted/vesting.
• Recorded Q3 2025 revenue of $0.7M (including $0.34M staking rewards); Q3 net loss was $352.8M, driven by a $625.2M derivative liability on 2025 stapled warrants, $194.7M financing costs (mostly non-cash), and a $30.5M unrealized loss on SOL.
• Derivative liability (fair value) for 2025 stapled warrants was $625.2M at Sep 30; change in fair value recognized a $423.3M non-cash gain in Q3 due to stock price decline.
• Massive potential dilution outstanding: 73.94M stapled warrants (liability-classified), 35.63M pre-funded warrants, and 7.39M advisor warrants (exercise price $0.001), among others.
• Subsequent to quarter-end: sold 954,617 shares via ATM netting $15.4M; authorized a $100M share repurchase program on Nov 3, 2025 (no purchases yet).
• Further accumulated SOL post-quarter; as of Nov 18, 2025 held or had rights to 2,340,757 SOL; SOL price fell 37% to $131 on Nov 17 from $208.70 at quarter-end (disclosed as subsequent event, no remeasurement).
• PoNS business: filed 510(k) on Sep 25, 2025 for stroke indication expansion (Breakthrough Device Designation); CMS final rates: controller $532.27 (effective Apr 1, 2025) and mouthpiece $2,963.30 (effective Jan 1, 2025); initial commercial payer approvals (Anthem, United, Aetna) and VA sales via Lovell.
• Going concern doubt from 2024 alleviated; management expects liquidity for at least 12 months but financial condition is highly dependent on SOL market price and liquidity.

Sentiment

Score: 3

Explanation: Liquidity improved and strategy pivot executed, but extreme dilution risk, large derivative liabilities, negative equity, and heavy dependence on SOL price (which declined 37% post-quarter) weigh heavily on risk-reward.

Positives

• Liquidity improved: cash and cash equivalents of $124.1M and working capital of $122.5M at Sep 30, 2025.
• Built sizable SOL position: 1,739,355 SOL at fair value of $350.2M as of Sep 30, 2025; staking commenced with $0.34M rewards recognized in Q3.
• Raised $502.8M gross ($374.9M net cash) in September PIPE; additional $8.8M (Q3) and $15.4M (post-Q3) via ATMs.
• No debt outstanding under the Master Loan Agreement as of Sep 30, 2025.
• PoNS regulatory/commercial momentum: 510(k) filing for stroke label expansion (Sep 25, 2025) and established CMS rates; initial major payer approvals (Anthem, United, Aetna) and VA/GSA channel active.
• Authorized a $100M share repurchase program on Nov 3, 2025, signaling potential capital return.
• Nasdaq compliance regained in 2025 (bid price and stockholders’ equity), reducing listing risk.

Negatives

• Q3 2025 net loss of $352.8M and YTD net loss of $366.4M, primarily from warrant derivative accounting and financing costs.
• Large derivative warrant liability of $625.2M at Sep 30, 2025 and $195.2M financing costs (mostly non-cash advisory warrants and stock to agents).
• Stockholders’ equity turned negative: $(152.4)M at Sep 30, 2025.
• Significant potential dilution: 73.94M stapled warrants, 35.63M pre-funded warrants, and 7.39M advisor warrants outstanding; total warrants and pre-funded instruments materially exceed current basic shares.
• High concentration risk: substantially all treasury assets in SOL; subsequent 37% drop in SOL price to $131 on Nov 17, 2025 increases downside risk.
• Unrealized loss on digital assets of $30.5M recognized in Q3 as SOL declined into quarter-end.
• Ongoing reliance on capital markets (ATMs) to fund operations and scale SOL treasury.

Risks

• Extreme SOL price volatility and liquidity risk materially affecting results and equity value; SOL fell 37% post-quarter (to $131 on Nov 17, 2025).
• Concentration risk: majority of assets are SOL; limited diversification amplifies downside exposure.
• Counterparty risk with custodians, exchanges, validators, and potential lending/DeFi activities; legal treatment of custodially held digital assets in insolvency remains uncertain.
• Regulatory risk: evolving U.S. and international crypto regulation; potential security classification of SOL could implicate Investment Company Act considerations.
• Operational and cybersecurity risks including loss/theft of private keys, smart contract vulnerabilities, and protocol-level events (forks, 51% attacks, outages).
• Significant warrant overhang and derivative liabilities could pressure share price and create earnings volatility.
• Liquidity of staked or locked SOL may be constrained by vesting/unbonding, limiting rapid monetization.
• Nasdaq continued listing risk if future bid-price or equity thresholds are breached, especially after cumulative reverse splits.

Future Outlook

Plan to continue scaling SOL holdings over the next 12–24 months using ATMs and other capital markets tools, deploy SOL into native staking and evaluate lending/DeFi opportunities to generate yield, and pursue PoNS label expansion (stroke) while relying on existing liquidity; performance remains highly sensitive to SOL price and market conditions.

Management Comments

• Objective is to maximize SOL per share via a best-in-class capital markets program and onchain opportunities, offering public investors direct exposure to Solana’s secular growth.
• Management expects existing resources to fund operations for at least 12 months from the report date, though financial condition is substantially dependent on SOL price and liquidity.
• In the coming months, intend to build an initial SOL position and significantly scale holdings over 12–24 months and evaluate staking, lending, and other ecosystem opportunities.

Industry Context

The company is positioning itself as a publicly traded SOL-focused treasury vehicle, analogous to Bitcoin treasury/pseudo-ETF strategies (e.g., MicroStrategy with BTC) but differentiated by SOL’s native staking yield. This comes amid expanding institutional interest in crypto but heightened regulatory scrutiny and counterparty risks; SOL-specific exposure concentrates risk versus diversified crypto strategies.

Comparison to Industry Standards

• Compared to MicroStrategy (BTC treasury), Solana Company is concentrated in SOL rather than BTC and seeks yield via staking (~7% protocol-level), whereas BTC is non-yielding; however, SOL carries higher regulatory/technical risk and less established institutional adoption.
• Unlike crypto miners (e.g., Marathon Digital, Riot Platforms) that generate coins via mining operations and have capex-heavy profiles, Solana Company is a treasury vehicle reliant on capital markets and staking; earnings volatility is driven by mark-to-market and derivative liabilities rather than mining economics.
• Versus diversified crypto firms (e.g., Galaxy Digital, Coinbase), Solana Company lacks revenue diversification and is more exposed to single-asset risk (SOL) and warrant-related dilution, which is atypical for traditional corporate treasuries.
• Use of complex, liability-classified warrants (Monte Carlo valuation, soft-call features) creates GAAP volatility beyond typical corporate capital structures, contrasting with industry norms for plain-vanilla equity/debt financing.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings disclosed; not aware of any pending or threatened matters expected to have a material adverse effect.

Related Party Transactions

• Strategic Advisory Agreement with Pantera Capital and Summer Wisdom; advisor warrants issued (7,394,119 total at $0.001 exercise price); pass-through expenses owed to Summer ($0.2M as of Sep 30, 2025).
• Trading Advisory Agreement with Pantera to manage substantially all digital assets/cash (10-year term); management fee 1.0% ≤$1B AUM, 0.75% $1–$5B, 0.50% >$5B; $0.2M payable as of Sep 30, 2025.

Stakeholder Impact

• Shareholders: significant potential dilution from stapled, pre-funded, and advisor warrants; authorization for $100M share repurchases may offset if executed.
• Employees: accelerated vesting of outstanding options approved; larger equity pool increases incentive capacity.
• Customers (PoNS): potential access expansion via CMS coding/rates, payer approvals, VA/GSA channels; pending stroke label expansion could broaden indication.
• Suppliers/Validators/Custodians: increased activity and fees tied to staking and custody relationships.
• Creditors: minimal debt outstanding; financial results highly sensitive to SOL market movements.

Next Steps

• Scale SOL holdings over the next 12–24 months using capital markets, including continued use of ATMs.
• Deploy SOL into staking and explore lending/DeFi opportunities to generate yield.
• Advance FDA 510(k) review for PoNS stroke indication and continue payer/reimbursement expansion.
• Potential opportunistic execution of the $100M share repurchase authorization.
• Maintain risk management around custodians, validators, and derivative warrant structures; monitor warrant amendments.

Key Dates

Recommendation

Despite improved liquidity, the investment case hinges on a single, highly volatile asset (SOL). The quarter reveals substantial negative equity, a $625M derivative liability, large non-cash financing charges, and an exceptionally dilutive warrant overhang. The disclosed 37% SOL price decline post-quarter further elevates downside risk. Until dilution and derivative overhang are clarified and SOL market risk moderates, risk/reward skews negative.

Keywords

Solana, SOL, digital asset treasury, staking, PIPE offering, stapled warrants, pre-funded warrants, derivative liability, Pantera Capital, Summer Wisdom, ATM program, PoNS, FDA 510(k), CMS reimbursement, share repurchase